Etomidate vs. Midazolam for Sedation During ERCP

• Status: Completed
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A receptor has been known that it maintains the appropriate sedative levels and affects little effects on respiratory system.

The investigators are now trying to investigate that etomidate with meperidine combination regimen is superior to the midazolam with meperidine more effective and less harm on sedation during the ERCP procedure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cheju Halla General Hospital
• Treatments: Etomidate; Meperidine; Midazolam

Criteria

Inclusion Criteria:

• All patients who are scheduled diagnositic or therapeutic ERCP.

• Age : more than 20 and less than 90 years old

• ASA(American Society of Anesthesiologists) classificiation : I, II, III

Exclusion Criteria:Patients following

• Refuse to be enrolled

• ASA American Society of Anesthesiologists)classification IV, V

• Breast feeder

• The mentally ill

• Drug abuser

• Hypersensitivity to sedative or opioids

• Alcohol intoxication or dependency

• Body mass index (BMI) 36kg/m2 or more

• Unstable vital sign

1. tachypnea, respiration rate more than 25/min or less than 10/min

2. Oxygen saturation : 90% or less

3. Systolic blood pressure : less than 90 mmHg or more than 180 mmHg

4. Diastolic blood pressure : less than 50 mmHg or more than 100 mmHg

5. Heart rate : more than 120 beat/min or less than 50 beat/min.